Evidence map›Paper›PMID 41721302›Full record

ArticleBMC cancer2026

Enhancing cervical cancer screening uptake through self-sampling for HPV DNA testing: insights and results from implementing in routine HIV clinics serving women living with HIV in Nairobi, Kenya, 2021-2024.

Rebeccah Wangusi, Evelyn Ngugi, Sam Wafula, Patrick Awuor, Emmah Momanyi, Rose Nyaboke, Violet Makokha, Joshua Orawo, Wilson Kariuki, Cyrus Gichaga and 12 more

Abstract read
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Rebeccah WangusiCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya. rwangusi@cihebkenya.org.
Evelyn NgugiDivision of Global HIV & TB (DGHT), Global Health Center (GHC), U.S. Centers for Disease Control & Prevention (CDC), Nairobi, Kenya.
Sam WafulaCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya.
Patrick AwuorCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya.
Emmah MomanyiCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya.
Rose NyabokeCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya.
Violet MakokhaCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya.
Joshua OrawoCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya.
Wilson KariukiCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya.
Cyrus GichagaCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya.
Anthony KiplagatNairobi City County Department of Health, Wellness and Nutrition, Nairobi, Kenya.
Caroline NgunuNairobi City County Department of Health, Wellness and Nutrition, Nairobi, Kenya.
Robert RiangaNairobi City County Department of Health, Wellness and Nutrition, Nairobi, Kenya.
Immaculate MutisyaDivision of Global HIV & TB (DGHT), Global Health Center (GHC), U.S. Centers for Disease Control & Prevention (CDC), Nairobi, Kenya.
Kenneth MasamaroDivision of Global HIV & TB (DGHT), Global Health Center (GHC), U.S. Centers for Disease Control & Prevention (CDC), Nairobi, Kenya.
Frank BasiyeDivision of Global HIV & TB (DGHT), Global Health Center (GHC), U.S. Centers for Disease Control & Prevention (CDC), Nairobi, Kenya.
Christina MwachariCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya.
Stella NjugunaDivision of Global HIV & TB (DGHT), Global Health Center (GHC), U.S. Centers for Disease Control & Prevention (CDC), Nairobi, Kenya.
Abraham KatanaDivision of Global HIV & TB (DGHT), Global Health Center (GHC), U.S. Centers for Disease Control & Prevention (CDC), Nairobi, Kenya.
Caroline NgenoCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya.
Emily KoechCenter for International Health, Education and Biosecurity (CIHEB) - Kenya, Nairobi, Kenya.
Ann ChaoCenter for Global Health, U.S. National Cancer Institute (NCI), Rockville, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn sub-Saharan Africa (SSA), only 14% of women aged 30 to 49 years have been screened for cervical cancer even though the region accounts for a quarter of global cervical cancer deaths. Women living with HIV are six times more likely to develop cervical cancer as compared to HIV-uninfected women in SSA. Unlike traditional screening methods such as Visual Inspection with Acetic Acid (VIA), the self-sampling for Human Papillomavirus (HPV) DNA testing offers a promising alternative as it reduces stigma, fear, and discomfort associated with cervical screening. However, evidence on its implementation in Kenya is limited. This study examined the feasibility and adoption of integrating self-sampling for HPV DNA testing in routine HIV clinics.

methodsBetween 2021 and 2024, HIV-infected women, aged 25 years and over, attending comprehensive care clinics in Nairobi, Kenya, were offered cervical cancer screening using self-sampling for HPV DNA testing. Data were abstracted from the Kenya electronic medical records (Kenya EMR) across 60 health facilities in Nairobi County. We present results, summary characteristics of the clients, and factors associated with testing HPV positive using self-sampling for HPV DNA testing.

resultsHPV DNA self-sampling accounted for 48.6% of cervical cancer screening tests. Of 14,227 women screened using self-sampling for HPV DNA testing, 3111 (21.9%) were HPV positive. Nearly half of the women who tested HPV positive (n = 1540; 49.6%) were eligible for rescreening using VIA; rescreening results showed that 133 (8.6%) were VIA positive. HPV genotyping showed HPV 16 and 18 positivity were 13.1% and 17.8%, respectively, with predominance of other high-risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) at 66.6% positivity. HPV positivity was associated with shorter duration on ART. Women who reported engaging in commercial sex were less likely to test HPV positive compared to women in the general population (10.3% versus 22.4%, respectively); this difference could not be explained by chance alone (ρ = 0.002).

conclusionResults show that integration of HPV self-sampling in routine clinics is both feasible and was readily adopted and integrated in HIV clinics in Kenya. It significantly increased overall cervical cancer screening rates and demand, reaching a larger proportion of women who were screened for the first time.

Indexed as

DNA, ViralEarly Detection of CancerHIV InfectionsHuman Papillomavirus DNA TestsHuman Papillomavirus VirusesPapillomavirus InfectionsUterine Cervical NeoplasmsAdultFemaleHumansKenyaMass ScreeningMiddle AgedPapillomaviridaeSpecimen HandlingDNA, ViralCervical cancerHIVHPV DNA self-samplingScreeningWomen

Identifiers

PMID41721302
PMCPMC13032437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.